Bioequivalence Study of Dapagliflozin 10 mg Film Coated Tablets in Healthy In…

This study aimed to demonstrate the bioequivalence of the Dapagliflozin 10 mg film-coated tablets manufactured by PT Dexa Medica, Indonesia, in comparison with the reference formulation, Forxiga® 10 mg filmcoated tablets, manufactured by AstraZeneca Pharmaceuticals

Dapagliflozin: A Review in Type 2 Diabetes

Dapagliflozin ( Forxiga®) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) and as add-on combination therapy (with other glucose-lowering agents, including insulin) for …

Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus…

Dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the associated weight gain in patients with inadequate control despite high doses of insulin.

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Di…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diab…

Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We conducted two randomised, double-blind, three-arm 24-week trials in treatment-naı¨ve patients to compare dapagliflozin plus metformin, dapagliflozin alone and metformin alone.